AHZ chart, page-35

Hi Terry

No argument that good results will make a lot of people take notice and yes this will depend on the level of detail. The results will give a level of understanding and confidence with immunisation potential but phase 2 will focus on therapautic trials. I was trying to suggest that I am not sure how much impact it will have on the SP as there is a long way to go.

I think we have seen before that positive news comes out and within a week the SP starts to fall and we all wonder why. I think we are all wiser now about the reasons but we still need to be a little cautious. The market is so unpredictable

IMO, it's the diversity of products that this company provides that makes it attractive to investors and as the Baillieu Holst's report suggests, there are 6 reasons to invest in AHZ and all of these factor in the SP.

The key will be confirmation of revenue trends from Cardiocel and other products and if they are tracking on making profits next year as predicted then institutions will definitely take more notice. Then you will see changes in the SP.

The trends of the last few days have been very positive and hopefully no more retracing. I do believe there is a lot to be confident about but not over confident just yet.